|
|
Volumn 18, Issue SUPPL.F, 1997, Pages
|
|
Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator
|
|
Author keywords
Acute myocardial infarction; Molecular biology; Reteplase; Thrombolytic therapy
|
|
Indexed keywords
ALTEPLASE;
FIBRIN;
FIBRINOLYTIC AGENT;
RECOMBINANT PLASMINOGEN ACTIVATOR;
RETEPLASE;
TISSUE PLASMINOGEN ACTIVATOR;
ACUTE HEART INFARCTION;
BLEEDING;
BLOOD CLOT LYSIS;
BRAIN HEMORRHAGE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DELETION MUTANT;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG PROTEIN BINDING;
DRUG STRUCTURE;
FIBRINOLYTIC THERAPY;
GENETIC ENGINEERING;
HUMAN;
NONHUMAN;
POINT MUTATION;
PRIORITY JOURNAL;
RISK;
|
|
EID: 0030781794
PISSN: 0195668X
EISSN: None
Source Type: Journal
DOI: 10.1093/eurheartj/18.suppl_f.11 Document Type: Conference Paper |
|
Times cited : (31)
|
|
References (32)
|
